Substituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient‐Derived Glioma Cells Authors: Carina J Dumo, Peter J Choi, Yuge Liu, Osaid Muhammad, Jason A Correia, Mike Dragunow, Thomas I‐H Park, Jiney Jose Published: 2026 ABSTRACT AbstractBrain tumors, specifically high‐grade gliomas such as glioblastoma (GBM), are challenging to treat due to the presence of physiological barriers such as blood–brain barrier (BBB) and tumor heterogeneity. Designing drugs that address these brain tumor‐specific drug discovery challenges will herald much‐needed breakthroughs for this patient population. This study presents a proof of concept for the in vitro cellular activity of the multitargeted kinase inhibitor crizotinib conjugated to BBB‐crossing heptamethine cyanine dyes decorated with various functional groups in four patient‐derived GBM cell lines. We also present evidence of cellular uptake, which contributes to the observed improvement in potency of the conjugates.Keywords: crizotinib, glioblastoma, heptamethine cyanine dyes, kinase inhibitors Background Crizotinib, a first‐generation ALK, c‐MET, ROS1 inhibitor was the first approved tyrosine kinase inhibitor for the treatment of ALK‐positive or ROS1‐positive metastatic nonsmall cell lung cancer (NSCLC) [1]. It binds the ATP‐binding site of the kinase domain and therefore causes inhibition of several downstream mediators such as STAT3, Akt, and phospholipase C gamma. All of these mediators promote tumor cell survival and proliferation. This leads to inducing G1‐S cell cycle arrest and triggers apoptosis [2]. It has been largely replaced by next‐generation inhibitors for treatment purposes due to the poor blood–brain barrier (BBB) penetration [3], resulting in suboptimal therapeutic dosage in intracranial tumors resulting from NSCLC metastasis to brain. Nevertheless, ALK and MET, targets of crizotinib, are reported to be overexpressed in glioblastoma (GBM) stem cell (GSC) in subpopulation of GBM patients [4]. GSC contributes to the development of therapeutic resistance in GBM [5] and therefore targeting and eradicating these GSCs could, in theory, improve the response to several anticancer agents, including crizotinib. There have been a few clinical trials (Table 1) evaluating the use of crizotinib in brain cancer. Hence, repurposing crizotinib by improving its BBB penetration can expand its utility for the treatment of primary and secondary intracranial tumors resulting from brain metastasis. Emerging evidence suggests that adding crizotinib to treating GBM patients along with temozolomide (TMZ), an alkylating agent commonly used to treat GBM, may provide therapeutic benefit. The combination of crizotinib with radiation therapy and temozolomide (TMZ), the frontline chemotherapy in a small cohort of GBM patients (37), resulted in improved overall survival (from 14.6 to 24 months) in phase 1b GEINO 1402 Trial [6]. These survival benefits may be enhanced across a broader patient population by optimizing crizotinib concentrations in the tumor tissue. TABLE 1Brain cancer clinical trials based on crizotinib.NCT numberDrug usedSelect CNS outcomes measuredNCT05204628CrizotinibCNS‐ORR, CNS‐DORNCT06564324CrizotinibCNS‐ORR, CNS‐TTP, CNS‐DOR, at 6, 12, 18, 24, 36 monthsNCT03052608CrizotinibCNS‐ORR, CNS‐TTP, CNS‐DRNCT04632758CrizotinibCNS ORR (IRC + INV), time to CNS progressionNCT04603807Entrectinib and crizotinibCNS‐ORR, CNS‐DORNCT06569420CrizotinibCNS‐ORR, CNS‐DOR, CNS‐TTP Note : CNS‐ORR (Central Nervous System Objective Response Rate): The proportion of patients with measurable CNS lesions (e.g., brain metastases) who experience a tumor shrinkage meeting predefined criteria. CNS‐DOR (Central Nervous System Duration of Response): The length of time that the CNS tumor response (CR or PR) is maintained before progression or death. CNS‐TTP (Central Nervous System Time to Progression): Time from a defined starting point (often treatment initiation) until disease progression occurs in the CNS (e.g., growth of brain metastases or development of new CNS lesions). Brain cancer clinical trials based on crizotinib. Note : CNS‐ORR (Central Nervous System Objective Response Rate): The proportion of patients with measurable CNS lesions (e.g., brain metastases) who experience a tumor shrinkage meeting predefined criteria. CNS‐DOR (Central Nervous System Duration of Response): The length of time that the CNS tumor response (CR or PR) is maintained before progression or death. CNS‐TTP (Central Nervous System Time to Progression): Time from a defined starting point (often treatment initiation) until disease progression occurs in the CNS (e.g., growth of brain metastases or development of new CNS lesions). So‐called tumor‐seeking dyes, especially heptamethine cyanine dyes (HMCD) [7, 8], include at least a select few that also possess the unique property of crossing the BBB [9, 10]. Their penetration into the brain parenchyma is facilitated by the overexpression of certain isoforms of organic anion‐transporting polypeptides (OATPs) at the BBB, especially OATP1A2 and in the GBM tumor tissues (OATP1A2, 2B1, 1C1, and 4A1) [11]. Research groups have exploited these properties by chemically attaching various drug molecules to HMCDs to improve tumor tissue specificity and efficacy, particularly in the design of therapies for various cancers [12, 13, 14, 15, 16, 17, 18, 19]. One such drug–dye conjugate, DZ‐002, a combination of HMCD dye and platinum‐based drug developed by Da Zen Theranostics, is undergoing phase 2 clinical trials for treating metastatic nonfamilial adenocarcinoma [20]. These developments raise the prospect of investigating these dye molecules in the context of elaborating their application for brain cancer therapy. We previously reported the evaluation of a crizotinib–HMCD dye IR786 conjugate on a patient‐derived GBM cell line, showing potent cytotoxic activity compared to crizotinib alone [21]. Pflug and colleagues [12] evaluated the crizotinib–IR786 conjugate in an orthotopic intracranial GBM xenograft model, with the conjugate exhibiting increased localization within brain tumors, reduced tumor growth, and prolonged survival. Based on these findings, the authors rightly concluded that conjugation to an HMCD improved intracranial tumor delivery and enhanced the therapeutic activity of crizotinib in preclinical glioma models. More recently, our group [19] published a follow‐up study evaluating the crizotinib–IR786 conjugate formulated in mPEG‐PLA micelles for intranasal administration. The rationale was to exploit both the tumor‐targeting properties of the HMCD and a nose‐to‐brain delivery strategy. We demonstrated that the micellar formulation retained cytotoxic activity against GBM cells in vitro and, in a preliminary orthotopic GBM model, showed accumulation within GBM tumors following intranasal delivery. The study therefore provided proof of concept that the conjugate could reach intracranial tumors via a nose‐to‐brain route. Despite the promising results reported in these studies, several important gaps remain. While both papers showed accumulation of the conjugates within intracranial tumors, they did not provide quantitative measurements of BBB permeability, such as maximum tolerated dose, brain‐to‐plasma concentration ratios, unbound brain exposure, or detailed pharmacokinetic analyses. Consequently, it remains unclear whether the observed tumor localization results from improved BBB penetration, disruption of the blood‐tumor barrier, enhanced tumor retention, or a combination of these factors. Alarmingly, we also observed accumulation of crizotinib–IR786 in various organs, including the lung, heart, liver, stomach, spleen, kidney, and intestine, suggesting that IR786 is not an ideal drug delivery agent for GBM treatment. This unwanted accumulation in the aforementioned organs may arise from lipophilicity and other physicochemical properties that were not systematically evaluated in these studies. Neither study explored how structural modifications to the cyanine dye scaffold influence the uptake, distribution, or efficacy. Instead, they focused on individual dye–drug conjugates and their biological performance. As a result, the field still lacks a structure–activity relationship describing how changes in dye substituents affect drug uptake and tumor targeting. From this perspective, the work detailed in this article tries to address a distinct and currently underexplored question. Whereas the previous studies demonstrate that a HMCD–crizotinib conjugate can accumulate in glioma tumors and exhibit therapeutic activity in vivo, they do not explain how structural variation within the dye scaffold influences uptake behavior. The investigation of substituent effects therefore has the potential to provide design principles that are largely absent from the current literature and could guide the future development of optimized cyanine dye‐mediated drug delivery systems. To optimize the physicochemical properties of HMCD–crizotinib conjugates, we introduced carboxylic acid and sulfonic acid side chains on the HMCD dye and evaluated the overall uptake in four patient‐derived GBM cell lines. We synthesized four drug–dye conjugates with crizotinib as the drug counterpart and HMCD dyes bearing carboxylic acid or sulfonic acid side chains, or side chains devoid of these hydrophilic groups. These conjugates were evaluated in four patient‐derived GBM cell lines, followed by an assessment of their uptake and retention. Results The synthesis of four drug–dye conjugates was accomplished, as shown in Schemes 1–3. The conjugate 1a is a crizotinib attached to HMCD known as MHI‐148 (1) and was synthesized via a route previously established by our group [22]. It started with the attachment of crizotinib to indole carboxylic acid 5, affording the key intermediate 6 (Scheme 1). This transformation was achieved through amide bond formation under mildly acidic conditions using EDCI as the coupling reagent in the presence of p‐toluenesulfonic acid. With intermediate 6 in hand, indole carboxylic acid 5 was subjected to a Vilsmeier–Haack reaction to furnish compound 7, which subsequently underwent coupling with intermediate 6 to yield the drug–dye conjugate 1a. Synthesis of drug–dye conjugate 1a from HMCD MHI‐148 (1). Synthesis of drug–dye conjugate 2a from unsymmetrical HMCD 2. Drug–dye conjugates 2a and 3a were prepared by the nucleophilic displacement of the chloride group of HMCD dyes 2 and 3, respectively, with crizotinib (Scheme 2). Although the reaction was complete with heating at 100 °C for 5 h in dimethylformamide, there were closely running impurities which diminished the yield of the expected conjugates. Synthesis of drug–dye conjugates 2a and 3a from HMCDs with sulfonic acid side chains. The conjugate 4a was prepared by coupling crizotinib to the HMCD 4 through amide bond formation using EDCI and p‐toluenesulfonic acid in dimethylacetamide (Scheme 3). The syntheses of HMCDs 2, 3, and 4 have been previously reported by our group [9]. Concentration–response assays were performed on four patient‐derived primary GBM cases to evaluate the synthesized drug–dye conjugates and compared to the corresponding dyes (Figure 1a,c). Hoechst‐positive and EdU‐positive cell curves revealed that only two conjugates, 1a and 4a, displayed greater potency than crizotinib alone, as shown by the leftward shift of both curves. In contrast, both sulfonic acid dye conjugates, 2a and 3a, and the corresponding sulfonic acid dyes stayed to the right of the crizotinib curve (Figure 1a,c). Comparative cell count and proliferation responses of crizotinib conjugates with different dyes. Four primary GBM cases were treated for 96 h with serial dilutions (256 pM to 100 µM) of four different dye and crizotinib conjugate pairs. Concentration–response curves for Hoechst‐positive cell count and EdU‐positive proliferation are shown in (a,c), with corresponding potency values summarized in (b,d) (mean ± SEM, n = 4). Statistical analyses of each conjugate to the MHI‐148 conjugate (1a) are indicated as **p < 0.01 (one‐way ANOVA with Holm‐Šidák post hoc test). Representative images of each treatment at 4 µM are shown in (e) (scale bar = 100 µm). The derived cell viability potency values (pEC50) supported these trends, showing that compound 1a had the highest potency at 6.23, and were significantly greater than all other conjugates, except 4a, which followed at 5.96 (p < 0.01; Table 2). All the dyes exhibited low cell viability potencies (pEC50 < 4.00; EC50 > 100 µM), with the exception of ethyl, carboxylic acid dye 4, which showed moderate potency (pEC50 = 5.11), comparable to the sulfonic acid dye conjugates. TABLE 2Summary of cell viability and proliferation potencies from various dye and crizotinib conjugate pairs.CompoundMean cell count potencyMean cytostatic potencypEC50 (±SEM)EC50 (µM ± SEM)pIC50 (±SEM)IC50 (µM ± SEM)Crizotinib5.30 (±0.07)4.99 (±0.84)5.68 (±0.13)2.08 (±0.62) 1 <4.00 (±0.00) >100 (±0.00)4.32 (±0.16)48.42 (±17.96) 1a 6.23 (±0.07)0.59 (±0.09)5.88 (±0.13)1.33 (±0.41) 2 <4.00 (±0.00) >100 (±0.00) <4.00 (±0.00) >100 (±0.00) 2a 4.90 (±0.10)**12.53 (±2.78)5.27 (±0.09)5.40 (±1.08) 3 <4.00 (±0.00) >100 (±0.00)4.12 (±0.12)76.38 (±20.49) 3a 4.85 (± 0.10)**14.26 (±3.12)5.40 (±0.32)3.95 (±2.91) 4 5.11 (± 0.03)7.71 (±0.49)5.52 (±0.06)3.01 (±0.40) 4a 5.96 (± 0.12)1.09 (±0.30)5.87 (±0.12)1.35 (±0.38)**Compared to conjugate 1a a significance value of p < 0.01. Summary of cell viability and proliferation potencies from various dye and crizotinib conjugate pairs. **Compared to conjugate 1a a significance value of p < 0.01. The cytostatic pIC50 values showed a similar profile. Conjugates 1a and 4a again produced the highest potencies at 5.88 and 5.87, respectively. The sulfonic acid conjugates 2a and 3a displayed lower potencies between 5.27 and 5.40. However, none of these differences was statistically significant from 1a. The dyes alone remained low in cytostatic activity, except for 4, which showed enhanced potency, approximately 16‐fold higher than 1, and exceeded the cytostatic potencies of all sulfonic conjugates (Figure 1 and Table 2). Representative images qualitatively show that at 4.0 µM, all dyes appeared similar to vehicle, except 4, which resembled closer to crizotinib (Figure 1e). Drug‐dye conjugates 1a and 4a resulted in complete inhibition of proliferation with pronounced reductions in cell number. In contrast, the sulfonic conjugates were visibly less effective. Together, these results indicate that 1a and 4a were the most potent drug–dye conjugates. To determine whether these compounds were taken up by cells, single‐cell flow cytometry was performed on a representative patient‐derived primary GBM case, utilizing the intrinsic fluorescence of the dyes for detection. In the far‐red channel, vehicle‐ and crizotinib‐treated cells exhibited mean fluorescent intensities comparable to the cell autofluorescence observed in the unstained control (Figure 2a). In contrast, all crizotinib conjugates displayed significantly greater fluorescent intensities than their corresponding dyes, ranging between 9.8‐ and 58.1‐fold higher (p < 0.0001). Among these, compound 4a exhibited the greatest fluorescence intensity, whereas the sulfonic acid conjugates (2a, 3a) displayed intensities approximately 7–9‐fold lower. Interestingly, the corresponding dye 4 also demonstrated greater fluorescence than the other dyes and reached levels comparable to those of the sulfonic acid dye conjugates (2a, 3a). Similar trends were observed for the percentage of cells positive for uptake, with all crizotinib conjugates showing significantly higher uptake than their dye counterparts, except dye 4, which also showed 100% positivity for the far‐red signal (p < 0.0001; Figure 2b). Representative spectral profiles and overlay plots of the far‐red signals are presented in the Supporting Information, highlighting the distinct fluorescent properties of the conjugates and dyes, as well as the relative signal intensities across all compounds (Figure S1). Cellular uptake of various crizotinib conjugates attached to different dyes in primary GBM cells. A representative primary GBM case was treated with vehicle (0.01% DMSO) or compounds at 100 nM for 2 h before analysis by single‐cell flow cytometry. Mean fluorescent intensities of controls and each dye and conjugate pair are shown in (a). The percentage of cells positive for far‐red fluorescence at channel R8 (excitation 670 nm, emission 812 nm) is shown in (b). Data presented as mean ± SEM (n = 3). Statistical analyses of each conjugate to their corresponding dye are indicated as *p < 0.0001 (one‐way ANOVA with Holm‐Šidák post hoc test). Discussions Evaluation of these HMCDs revealed that MHI‐148 (1) crizotinib conjugate 1a remained the most potent conjugate (Figure 1). In contrast, all sulfonic acid‐containing dye–crizotinib conjugates (2a, 3a) had significantly reduced cell viability and proliferation potency. Although this reduced potency could be attributed to the fact that excessive hydrophilicity can negatively impact cellular uptake [9, 23], we observed 100% of cells being positive for far‐red signal for both conjugates 2a and 3a. Therefore, the reduced cellular potency for these conjugates could be attributed to several other factors, such as differences in subcellular localization and insufficient target engagement following uptake. The distinct physicochemical properties of the conjugates, including polarity, charge distribution, and hydrophobicity, are likely to influence these factors. Further experimental studies are required to confirm the main mechanism of these observations. Multiple literature references imply and testify that cellular uptake and compound potency are not straightforward in most cases, with various factors influencing cellular compound potency [24, 25, 26]. While increased intracellular accumulation might enhance the likelihood of target engagement, total cellular uptake is inadequate for predicting the observed potencies. A clear distinction exists between total and free intracellular compound concentrations, with only the latter contributing to the observed biological effect [27]. The differing cellular activity and spectral profiles further suggest that the conjugates remain largely intact and chemically distinct following uptake. Previous studies have suggested that the meso‐chloro group of HMCDs can bind with albumin and facilitate cellular uptake, while its substitution with thiol‐based linkages resulted in faster hydrolysis and clearance [28, 29, 30]. But prior work has also shown that HMCD uptake in patient‐derived GBM cell lines was not fully abolished by inhibition of albumin binding, OATP transporters, or endocytosis separately, indicating that dye uptake occurs via multiple overlapping mechanisms [9]. Collectively, these findings suggest that while the meso‐chloro group may contribute to uptake kinetics, its role is likely secondary to the dye’s overall physicochemical properties. The two conjugates, 2a and 3a, lacked the meso‐chloro group, and their reduced potency might be due to faster clearance, which needs to be ascertained. These findings emphasize the importance of designing and synthesizing conjugates with dyes that enhance cellular uptake while preserving the activity of the conjugated drug. The asymmetric ethyl‐carboxylic acid dye 4 exhibited unexpectedly high intrinsic activity in reducing cell count and proliferation, comparable to the sulfonic‐acid conjugates. This limits its suitability as a drug delivery carrier as an ideal carrier should exhibit minimal intrinsic toxicity. Until the mechanism underlying this atypical toxicity is understood, this scaffold cannot be reliably advanced. Single‐cell flow cytometry revealed that all crizotinib conjugates were taken up in all cells at a near 100% efficiency but exhibited varying fluorescent intensities. This was surprising as although previous studies demonstrated that sulfonic‐acid dyes had poor uptake [8], when crizotinib is conjugated, the proportion of cells positive for far‐red signal increases to 100%, suggesting that all cells have taken up some amount of compound. Future studies could investigate whether the amount of intracellular accumulation or subcellular localization differs relative to the corresponding HMCDs used, which may provide greater insight into the structure–activity relationship. Regardless, the MHI‐148 conjugate, 1a, consistently demonstrated the greatest overall potency with high overall cellular uptake while maintaining low intrinsic dye toxicity, supporting its continued selection for further development. Conclusions The above medicinal chemistry campaign explored the effect of hydrophilic substituents on the HMCD dye counterpart of the drug–dye conjugate. The conjugates were evaluated on four patient‐derived GBM cell lines, which furnished interesting insights into the cell count and proliferation potencies of such conjugates based on the hydrophilic group attached to the dye. Conjugates based on MHI 148, a carboxylic acid‐containing HMCD dye, tend to enhance the potency of the drug (crizotinib) attached, whereas conjugates derived from sulfonic acid‐containing HMCD dyes have substantially reduced cellular activity despite a similar uptake profile. The mechanism leading to this differential behavior is currently under investigation. The results obtained provide further impetus for fine‐tuning physicochemical properties of HMCD dyes as a drug delivery system for brain cancer drug development. Funding This study was supported by the Cure KIds/Hugh Green Foundation (5500) and Neurological Foundation of New Zealand (2027 PRG). Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supplementary Material Acknowledgments We thank Dr Adrian Blaser for the proton, carbon, and fluorine NMR analysis. Mr Sisira Kumara for the analytical HPLC analysis, Mr Sree Sreebhavan for high‐resolution mass spectra. We thank the brain tumor donors for their generous and precious gifts of brain tissue. We thank the Neurological Foundation, Cure Kids, the Kircassock Trust, and the Hugh Green Foundation (Funders of the Hugh Green Biobank) for funding the project. We also acknowledge Deane Endowment Trust funding for Carina Dumo. The graphical abstract was created using BioRender: Scientific Figure and Illustration Software. Open access publishing facilitated by The University of Auckland, as part of the Wiley ‐ The University of Auckland agreement via the Council of Australasian University Librarians. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Supplementary Materials Supplementary Material Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.